Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218127 · ClinicalTrials.gov registry record · Phase 2
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
A Phase 2 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT00218127 is a Phase 2 study of Opioid-Related Disorders and Heroin Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 142 participants, below the 344-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00218127, a Phase 2 study of Opioid-Related Disorders and Heroin Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Heroin dependence remains a major addiction problem in the United States. The purpose of this study is to determine the effectiveness of levoacetyl methadol (ORLAAM) in treating heroin dependent individuals.
Conditions Studied
Interventions
- DRUG Levoacetyl Methadol
Study Locations (1)
Texas
- Department of Psychatiry, Mental Services - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218127
The ClinicalTrials.gov registry entry for NCT00218127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 344-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (59% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Levoacetyl Methadol is the first listed.
NCT00218127 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00218127 about?
NCT00218127 is a clinical study titled "Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens". Heroin dependence remains a major addiction problem in the United States. The purpose of this study is to determine the effectiveness of levoacetyl methadol (ORLAAM) in treating heroin dependent individuals.
What is the current status of trial NCT00218127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2001-11. Estimated completion is 2005-07.
What conditions does trial NCT00218127 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Heroin Dependence.
What interventions are being tested in trial NCT00218127?
The interventions under investigation include: Levoacetyl Methadol (DRUG).
Who is sponsoring clinical trial NCT00218127?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218127 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.